latest update:
[TrialBase DB]

trial summary · NCT07900074

Mechanisms of Weight Loss: Tirzepatide vs Semaglutide

Mechanisms of Weight Loss Due to Dual GIP GLP-1 Receptor Agonism With Tirzepatide Compared to Semaglutide: A Randomized Controlled Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Obesity (Disorder), sponsored by McMaster University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07900074phase PHASE4enrollment 80start 2026-10-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes. The main questions it aims to answer are: \- Does tirzepatide have a greater effect on energy expenditure or energy extraction than semaglutide? Participants will: * Take tirzepatide or semaglutide once weekly for 12 weeks * Undergo identical baseline and week 12 study visits (including 24-hour whole room indirect calorimeter testing, MRI scan, body composition, 3-day meal plan and stool collection)

Source record: https://clinicaltrials.gov/study/NCT07900074

Facts

registry idNCT07900074
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE4
study typeINTERVENTIONAL
lead conditionObesity (Disorder)
sponsorMcMaster University
sponsor classOTHER
enrollment80
start date2026-10-31
primary completion2029-12-31
completion2029-12-31
results postednot reported

Conditions

  • Obesity (Disorder)

Interventions

  • Tirzepatide
  • Semaglutide

Countries

  • Canada

Intervention types: DRUG

Work with this record